Member Info for Laura2022

Would fit with this where the work would have bene completed by March/April 2024

4 August 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics ("Bicycle") that it expects to be completed over the next six months.  The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle programs.

In the last month you've posted 23 times on 3 shares you don't own ??

Very strange

Which shares would you recommend?

Bicycle Therapeutics

32,945 followers

1w

Hot off the press: Phase 1 dose escalation results for our investigational Bicycle® Toxin Conjugate BT5528 are now published in the Journal of Clinical Oncology: https://lnkd.in/dEUqJtS9. Our deepest thanks to the patients, physicians and clinical site staff who contributed to these data. We look forward to presenting updated data for BT5528 at #ESMO24 next week.

Thanks for that debull

Thanks KingH

What the article recommends is exactly what PYC offer isn't it?

The FDA Project Optimus, RACE Act and other regulatory initiatives (16) allow drug developers to create a new paradigm and strategy to tackle pediatric drug development. These new regulatory requirements and legislation also impact how drug developers devise binding regulatory documents such as Pediatric Investigation Plans (PIPs) for Europe and initial Pediatric Study Plans (iPSPs) for the USA. These include the evidence collection through non-clinical models, e.g., identification of appropriate cell lines and animal models, and the application of modeling and simulation/model-informed drug development (MIDD) to evaluate pharmacokinetic (PK)- pharmacodynamic (PD) or exposure/response (ER) relationships (17).

In this review article, we provide some key considerations when designing oncology clinical trials in pediatric populations and development strategies that can utilize all the available information with the support of quantitative approaches using PK-PD/ER to optimize the dosage in oncology pediatric populations.

It clearly says so IRON?

e sale process, which is predicted to complete by the end of the month, is expected to result in hostmore being wound up and delisted from the london stock exchange.

its uk restaurants, which have a new york-influenced food and ****tails menu, continue to stay open as normal.

russ mould, an investment director at aj bell, said it is “effectively game over for hostmore as a listed business”, adding: “the company’s share price crashed 90 per cent after an expansion plan went up in smoke, implying there is little to no value left in the listed business for shareholders.”

the plan to become fully-franchised formed part of a deal, struck in april, to merge with us-based tgi fridays inc, to create a larger firm that will remain listed in london.

but on monday, hostmore said it was no longer pursuing a takeover following a management change which means it would not be able to collect royalties from the tgi fridays brand.

Thanks

Crazy ..20p to 0 2p in 12mths

Is it de listing then please ?

It is the Board's present expectation that the Company (Hostmore plc), being the listed non-trading holding company of Thursdays, will be wound up and delisted contemporaneous with the conclusion of the sale process, as TGI Fridays in the UK will continue its operations under new ownership.

Strategic Review Update

In addition to the sale process for the Group's corporate stores, the Board undertook a Strategic Review with advisers to evaluate other potential options to secure value for the Group. The Strategic Review has now completed and confirmed that none of these potential options, individually or collectively, is presently likely to provide value to the Group. However, the Board will continue to actively explore other potential options in response to events and will proactively pursue any opportunities that become available.

Thanks once again Ralph

Key phrase

"area that is rightfully getting more and more attention in drug development.”

Physiomics’ expertise in Model-Informed Drug Development (MIDD) can inform or de-risk their development decisions.

 

Dr Peter Sargent, CEO, commented: “I’m really excited to attend BioForward to meet with leaders of early-stage and emerging biotech’s that can reap the benefits of early integration of Model Informed Drug Development in their pipeline strategy. An area that is rightfully getting more and more attention in drug development.”

If you are interested in meeting at BioForward, please contact us through the partnering system.

Wrong

BSFA has no business, no revenues to speak of and was just a play on ethical leather!! ...not a great revolutionary/cost effective business plan

What is fair price given the news please ?

Thankyou Mikey

I will monitor things and with such a medically important product I hope they flourish

Best wishes

L

From the same report

detail in Note 2 to the interim financial statements, the Board has concluded (as it did in the annual reports for the years ended 30 September 2022 and 30 September 2023) that there continues to be a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern.

Thankyou Mikey

Operating loss £5.99m (H1 2023: £4.76m)

This was last half years, raised another £9mln in March

Now in Sept it seems they may be down to last £3mln...revenues of only £377k

Will see how things progress

These read really well...might the muted response be this ?

Cost of Sales

Cost of sales rose by 175% to £2.2 million (H1 2023: £0.8 million) reflecting the rise in sales volumes. Gross profit on Eroxon® sales increased by 90% to £1.7 million (H1 2023: £0.9 million) Gross profit margins on Eroxon® sales reduced to 44% (H1 2023: 54%) reflecting, as previously disclosed, an increase in manufacturing costs in order ensure we meet increased capacity requirements, which is expected to normalise in 2025.

Operational costs

Total operational costs were £4.0 million (H1 2023: £2.9 million) and comprised of research and development costs of £0.6 million (H1 2023: £0.8 million) and operating expenses of £3.4 million (H1 2023: £2.1 million) which included non-cash share-based payments charge of £1.3 million (H1 2023: £0.7 million) with the remaining rise in costs predominantly relating to the short-term investment into supply chain, investment required to increase manufacturing capacity and ensure continuity of supply. Other core operating costs remain relatively static.

Morning NK/KingH

We know, as yiu say , this is ludicrous undervalued in terms of revenues + cash versus market value

A clear and integrated tie up with DoseMeRx could be huge